Clinical Trial

Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function

Study acronym: NATURE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving treatment for children with relapsed or resistant leukemia and other life-threatening hematological and hereditary disorders. In Denmark, around 25 children undergo allogeneic HSCT every year, of these approximately 85-90% survive into adulthood. The goal of this observational study is to learn about neurocognitive outcomes in children undergoing (HSCT) and to understand which clinical, physical, and environmental factors may affect neurocognitive development during the first year after transplant. The main questions it aims to answer are: How does neurocognitive function change from before HSCT to one year after transplantation in pediatric patients? Which clinical, physical, and environmental factors are linked to better or worse neurocognitive outcomes? Participants will: Complete neurocognitive tests before HSCT and at 1-year follow-up, covering intelligence, memory, attention, executive function, processing speed, and motor skills. Undergo physical tests before HSCT, at hospital discharge, at 6-months follow-up, and at 1-year follow-up, including muscle strength, mobility, endurance, balance, and cardiopulmonary fitness (only at 1-year follow-up). Wear activity trackers to measure physical activity and sedentary time during hospitalization at 6 months and 1-year post-HSCT. Complete questionnaires about sleep, pain, quality of life, fatigue, family background, and exposure to outdoor and green spaces. Have medical records reviewed for treatment-related side effects, immune recovery, inflammation, and pain management. This study will help understand how neurocognitive function develops after HSCT in children and which factors (clinical, physical, or environmental) may support better recovery and well-being.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-06.
Trial Details
NCT Number NCT07408713
Lead Sponsor Rigshospitalet, Denmark
Collaborators: Jascha Fonden, The Dagmar Marshall Foundation, Gangsted Foundation
Conditions HSCT, Pediatric Cancer, Pediatric Patients, Late Effect, Toxicity, Neurocognitive Dysfunction, Physical Function, Physical Capacity
Enrollment 100 participants
Start Date 2026-02-15
Primary Completion 2031-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-20